Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) disclosed results from its Phase 3 MARIPOSA study, indicating that RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib) significantly extended overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) with specific mutations when compared to osimertinib.
The data, presented at the 2025 European Lung Cancer Congress, showed that the median OS for patients treated with the RYBREVANT® combination has not been reached, suggesting ongoing survival benefits beyond the current median follow-up of 37.8 months. In contrast, the median OS for osimertinib-treated patients was 36.7 months. The study claims that the RYBREVANT® combination could extend median OS by at least one year compared to osimertinib. This development comes as J&J demonstrates strong financial stability with a healthy EBITDA of $29.9 billion and maintains a 54-year streak of dividend increases, currently yielding 3.1%.
Professor Nicolas Girard, trial investigator, emphasized the widening gap between the survival curves for the two treatments, underlining the potential for improved patient outcomes with the RYBREVANT® combination.
The study also reported that RYBREVANT® plus LAZCLUZE™ prolonged time to symptomatic progression (TTSP) by over 14 months versus osimertinib, suggesting a longer preservation of quality of life before the emergence of lung cancer symptoms.
RYBREVANT® plus LAZCLUZE™ is already approved in the United States, Europe, and other markets for first-line treatment of EGFR-mutated NSCLC. The new OS results are expected to be shared with health authorities globally.
The safety profile for the combination therapy was consistent with previous analyses, showing comparable adverse event (AE) rates to other RYBREVANT® regimens and no new safety signals with longer-term follow-up. The study indicates that implementing prophylactic measures during the first four months of treatment could significantly reduce the risk of certain side effects.
The MARIPOSA study, which enrolled 1,074 patients, previously met its primary endpoint in October 2023, showing a significant improvement in progression-free survival (PFS) compared to osimertinib.
This report is based on a press release statement from Johnson & Johnson.
In other recent news, Johnson & Johnson has unveiled promising results from its Phase 3 Vivacity-MG3 study, showing significant improvement in muscle strength for patients with generalized myasthenia gravis (gMG) using nipocalimab. This comes as the company also announced a substantial $55 billion investment in U.S. manufacturing and research facilities over the next four years, marking a 25% increase from previous investments. In the realm of cancer treatment, Johnson & Johnson reported breakthrough survival results from its Phase 3 MARIPOSA study for advanced non-small cell lung cancer, showcasing the potential of RYBREVANT® and LAZCLUZE™ to improve patient outcomes. Additionally, nipocalimab received FDA Fast Track designation for treating Sjögren’s disease, underscoring its potential in addressing unmet medical needs in autoimmune conditions. RBC Capital Markets has maintained an Outperform rating on Johnson & Johnson, citing the potential $5 billion annual sales opportunity for Icotrokinra, which could significantly contribute to the company’s growth in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.